We are live on ! Find out more
GWPH

GW Pharmaceuticals Plc American Depositary Shares
GWPH

Delisted

GWPH was delisted on the 4th of May, 2021.

204 hedge funds and large institutions have $3.03B invested in GW Pharmaceuticals Plc American Depositary Shares in 2017 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 53 increasing their positions, 59 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 26

44% more capital invested

Capital invested by funds: $2.1B → $3.03B (+$927M)

20% more funds holding in top 10

Funds holding in top 10: 56 (+1)

13% more funds holding

Funds holding: 181204 (+23)

10% less repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 59

12% less call options, than puts

Call options by funds: $75.8M | Put options by funds: $85.9M

Holders
204
Holders Change
+23
Holders Change %
+12.71%
% of All Funds
4.63%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.14%
New
51
Increased
53
Reduced
59
Closed
26
Calls
$75.8M
Puts
$85.9M
Net Calls
-$10M
Net Calls Change
+$16.7M
Name Holding Trade Value Shares
Change
Change in
Stake
SCM
1
Scopia Capital Management
New York
$456M +$54.9M +467,035 +16%
Capital Research Global Investors
2
Capital Research Global Investors
California
$446M +$39.4M +335,216 +11%
PP
3
Prudential plc
United Kingdom
$229M -$31.1M -264,397 -13%
Capital World Investors
4
Capital World Investors
California
$190M +$89.3M +760,079 +112%
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$132M +$4.33M +36,874 +4%
Janus Henderson Group
6
Janus Henderson Group
United Kingdom
$104M +$8.33M +70,854 +10%
BlackRock
7
BlackRock
New York
$102M -$6.58M -56,000 -7%
Citadel Advisors
8
Citadel Advisors
Florida
$94.3M +$64.6M +549,911 +335%
Fidelity Investments
9
Fidelity Investments
Massachusetts
$92.9M -$24.1M -205,522 -23%
CCM
10
Consonance Capital Management
New York
$89.2M +$8.63M +73,445 +12%
Bank of America
11
Bank of America
North Carolina
$67.9M -$8.19M -69,687 -12%
Jennison Associates
12
Jennison Associates
New York
$64.7M -$304K -2,590 -0.5%
Point72 Asset Management
13
Point72 Asset Management
Connecticut
$53M +$28.6M +243,322 +154%
Morgan Stanley
14
Morgan Stanley
New York
$50.9M +$14.9M +127,122 +49%
PAMU
15
Pictet Asset Management (UK)
United Kingdom
$48.2M +$1.15M +9,783 +3%
Invesco
16
Invesco
Georgia
$47.5M -$6.52M -55,490 -13%
RSCM
17
Rock Springs Capital Management
Maryland
$46.7M -$2.23M -19,000 -5%
DM
18
Deerfield Management
New York
$44.8M -$2.77M -23,544 -6%
AllianceBernstein
19
AllianceBernstein
Tennessee
$43.9M +$5.97M +50,780 +18%
Federated Hermes
20
Federated Hermes
Pennsylvania
$39.4M +$5.42M +46,100 +18%
Canada Pension Plan Investment Board
21
Canada Pension Plan Investment Board
Ontario, Canada
$36.3M +$32.3M +275,000 New
Victory Capital Management
22
Victory Capital Management
Texas
$34.5M +$1.88M +15,995 +7%
Mirae Asset Global Investments
23
Mirae Asset Global Investments
South Korea
$32.6M +$16.2M +138,199 +127%
Deutsche Bank
24
Deutsche Bank
Germany
$30.1M +$18.8M +159,783 +234%
BBA
25
Baker Bros. Advisors
New York
$29.3M +$17.2M +146,800 +196%

GWPH Hedge Fund Activity: Q4 2017 in Review

204 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in GW Pharmaceuticals Plc American Depositary Shares (GWPH) for Q4 2017, worth a combined $3.03B — up 44% from $2.1B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new GWPH positions and 26 closed out — a net gain of 25 holders — while 53 added to existing stakes and 59 trimmed.

The largest buyer was Capital World Investors, adding an estimated $89.3M. The largest seller was OrbiMed, cutting an estimated $60.7M.

  • 204 institutional investors held GW Pharmaceuticals Plc American Depositary Shares (GWPH) as of Q4 2017, up from 181 in Q3 2017.
  • Funds reported $3.03B of GW Pharmaceuticals Plc American Depositary Shares stock for Q4 2017, up 44% quarter-over-quarter.
  • 51 funds opened new GW Pharmaceuticals Plc American Depositary Shares positions in Q4 2017 and 26 closed out, a net change of +25 holders.
  • The largest GW Pharmaceuticals Plc American Depositary Shares buyer in Q4 2017 was Capital World Investors, an estimated $89.3M added.
  • The largest GW Pharmaceuticals Plc American Depositary Shares seller in Q4 2017 was OrbiMed, an estimated $60.7M sold.

Based on aggregated 13F filings for Q4 2017.